Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy – Results of a United Kingdom phase II trial (CNS 2007 04)

[1]  M. Woolley,et al.  Robot-guided convection-enhanced delivery of carboplatin for advanced brainstem glioma , 2013, Acta Neurochirurgica.

[2]  Peter Canoll,et al.  Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children. , 2013, Journal of neurosurgery. Pediatrics.

[3]  D. Hargrave,et al.  Pediatric diffuse intrinsic pontine glioma : can optimism replace pessimism ? Review , 2012 .

[4]  David T. W. Jones,et al.  K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas , 2012, Acta Neuropathologica.

[5]  W. Vandertop,et al.  Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. , 2012, Cancer treatment reviews.

[6]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[7]  Li Ding,et al.  Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas , 2012, Nature Genetics.

[8]  G. Margison,et al.  Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells , 2011, Melanoma research.

[9]  Barbara S. Paugh,et al.  Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  T. Zhou,et al.  Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. , 2011, Neuro-oncology.

[11]  D. Johnston,et al.  A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma. , 2010, European journal of cancer.

[12]  K. Hopkins,et al.  Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Sarin,et al.  Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. , 2010, International journal of radiation oncology, biology, physics.

[14]  C. Hawkins,et al.  Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Brandes,et al.  Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma , 2009, Cancer.

[16]  A. Brodbelt,et al.  Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy , 2009, British Journal of Cancer.

[17]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[18]  A. Brandes,et al.  Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Herman,et al.  Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Ellison,et al.  Young age may predict a better outcome for children with diffuse pontine glioma , 2008, Cancer.

[21]  T. Zhou,et al.  Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP‐16: A Children's Oncology Group phase II study , 2008, Pediatric blood & cancer.

[22]  S. Baruchel,et al.  Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. , 2006, European journal of cancer.

[23]  D. Hargrave,et al.  Diffuse brainstem glioma in children: critical review of clinical trials. , 2006, The Lancet. Oncology.

[24]  M. Mehta,et al.  Phase 1 study of concurrent RMP‐7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas , 2005, Cancer.

[25]  T. Morgan,et al.  Design of Phase II cancer trials evaluating survival probabilities , 2003, BMC medical research methodology.

[26]  A. Tolcher,et al.  Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules , 2003, British Journal of Cancer.

[27]  M. Berger,et al.  Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children's Cancer Group. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  D. Feeny,et al.  The Health Utilities Index (HUI®) system for assessing health-related quality of life in clinical studies , 2001, Annals of medicine.

[29]  V. Lanchote,et al.  Radiation therapy and high-dose tamoxifen in the treatment of patients with diffuse brainstem gliomas: results of a Brazilian cooperative study. Brainstem Glioma Cooperative Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  E. Bouffet,et al.  Radiotherapy followed by high dose busulfan and thiotepa , 2000, Cancer.

[31]  Wan Ariffin Bin Abdullah,et al.  Med Pediatr Oncol , 1999 .

[32]  A. Gholkar,et al.  UKCCSG study of accelerated radiotherapy for pediatric brain stem gliomas. United Kingdom Childhood Cancer Study Group. , 1997, International journal of radiation oncology, biology, physics.

[33]  R. Goodman.  The Strengths and Difficulties Questionnaire: a research note. , 1997, Journal of child psychology and psychiatry, and allied disciplines.

[34]  J. Krischer,et al.  Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study. , 1993, International journal of radiation oncology, biology, physics.

[35]  R. Zimmerman,et al.  Hyperfractionated radiation therapy (72 Gy) for children with brain stem gliomas A childrens cancer group phase I/II trial , 1993, Cancer.

[36]  J. Krischer,et al.  Pre‐irradiation chemotherapy and hyperfractionated radiation therapy 66 Gy for children with brain stem tumors. A phase II study of the pediatric oncology group, protocol 8833 , 1993, Cancer.

[37]  S. Suissa,et al.  Brain stem tumors in children: results of a survey of 62 patients treated with radiotherapy. , 1986, International journal of radiation oncology, biology, physics.

[38]  P. Varlet,et al.  Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma , 2011, Journal of Neuro-Oncology.

[39]  M. Mehta,et al.  A Phase I study of concurrent RMP‐7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas , 2005 .

[40]  J. Zucker,et al.  Carboplatin before and during radiation therapy for the treatment of malignant brain stem tumours: a study by the Société Française d'Oncologie Pédiatrique. , 2002, European journal of cancer.

[41]  J. Langston,et al.  Carboplatin and etoposide with hyperfractionated radiotherapy in children with newly diagnosed diffuse pontine gliomas: a phase I/II study. , 1998, Medical and pediatric oncology.